- Home
- RITR vs URGN Comparison
RITR vs URGN Comparison
Compare RITR & URGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RITR
- URGN
- Stock Information
- Founded
- RITR 2015
- URGN 2004
- Country
- RITR Hong Kong
- URGN United States
- Employees
- RITR N/A
- URGN N/A
- Industry
- RITR
- URGN Biotechnology: Pharmaceutical Preparations
- Sector
- RITR
- URGN Health Care
- Exchange
- RITR NYSE
- URGN Nasdaq
- Market Cap
- RITR 221.1M
- URGN 181.2M
- IPO Year
- RITR 2024
- URGN 2017
- Fundamental
- Price
- RITR $5.24
- URGN $14.82
- Analyst Decision
- RITR
- URGN Strong Buy
- Analyst Count
- RITR 0
- URGN 9
- Target Price
- RITR N/A
- URGN $26.81
- AVG Volume (30 Days)
- RITR 713.4K
- URGN 5.9M
- Earning Date
- RITR 02-15-2025
- URGN 08-12-2025
- Dividend Yield
- RITR N/A
- URGN N/A
- EPS Growth
- RITR N/A
- URGN N/A
- EPS
- RITR 0.09
- URGN N/A
- Revenue
- RITR $47,948,887.00
- URGN $91,871,000.00
- Revenue This Year
- RITR N/A
- URGN $36.65
- Revenue Next Year
- RITR N/A
- URGN $88.35
- P/E Ratio
- RITR $60.73
- URGN N/A
- Revenue Growth
- RITR 278.44
- URGN 8.98
- 52 Week Low
- RITR $2.24
- URGN $3.42
- 52 Week High
- RITR $8.75
- URGN $18.15
- Technical
- Relative Strength Index (RSI)
- RITR N/A
- URGN 73.80
- Support Level
- RITR N/A
- URGN $6.92
- Resistance Level
- RITR N/A
- URGN $15.22
- Average True Range (ATR)
- RITR 0.00
- URGN 1.57
- MACD
- RITR 0.00
- URGN 1.17
- Stochastic Oscillator
- RITR 0.00
- URGN 96.49
About RITR REITAR LOGTECH HLDGS LTD
Reitar Logtech Holdings Ltd provide one-stop solutions for logistics property operations in property development and redevelopment projects. It consists of two segments: construction management and engineering design services; and asset management and professional consultancy services in Hong Kong. Key revenue is generated from construction management and engineering design services.
About URGN UroGen Pharma Ltd.
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.